An overview of pazopanib in metastatic renal cell carcinoma (mRCC) in Ministry of Health (MOH), Malaysia: A multicentre experience

被引：0
|
作者：
Malwinder, S. [1 ]
Nurazzahra, K. [2 ]
Sandya, S. [2 ]
Chen, M. [1 ]
机构：
[1] Hosp Sultan Ismail, Dept Radiotherapy & Oncol, Johor Baharu, Malaysia
[2] Hosp Kuala Lumpur, Dept Radiotherapy & Oncol, Kuala Lumpur, Malaysia
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
277P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Is Pazopanib Safe and Efficacious in Patients with Metastatic Renal Cell Carcinoma?
    Bukowski, Ronald M.
    CURRENT ONCOLOGY REPORTS, 2010, 12 (02) : 77 - 79
  • [32] Pazopanib (p) or sorafenib (s) + radium-223 (rad) in metastatic renal cell carcinoma (mrcc) with bone metastases (bm)
    Bosse, D.
    McKay, R. R.
    Gray, K. P.
    Michaelson, M. D.
    Sleeper, C.
    Walsh, M.
    Krajewski, K. M.
    Jacene, H.
    Bellmunt, J.
    Pomerantz, M. M.
    Harshman, L. C.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [33] Efficacy and safety of pazopanib as a subsequent treatment after failure of other targeted agents in patients with metastatic renal cell carcinoma (mRCC).
    Tan, Jiahuai
    Heilbrun, Lance K.
    Fontana, Joseph A.
    Smith, Daryn
    Heath, Elisabeth I.
    Baranowski, Karen
    Vaishampayan, Ulka N.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [34] Real-word evidence in patients treated with pazopanib for advanced/metastatic renal cell carcinoma (mRCC): The APOLON study.
    Thiery-Vuillemin, Antoine
    Barthelemy, Philippe
    Lebret, Thierry
    Bigot, Pierre
    Stein, Ulrich
    Dourthe, Louis Marie
    Longo, Raffaele
    De La Cruz, Jeannine
    Sevaux, Sandra
    Tindel, Malka
    Albiges, Laurence
    Escudier, Bernard
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [35] Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma
    Rossetti, Sabrina
    D'Aniello, Carmine
    Iovane, Gelsomina
    Scagliarini, Sarah
    Laterza, Maria M.
    De Vita, Fernando
    Savastano, Clementina
    Carteni, Giacomo
    Porricelli, Maria A.
    Berretta, Massimiliano
    Pisconti, Salvatore
    Facchini, Gaetano
    Cavaliere, Carla
    FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [36] THE EFFECTS OF PAZOPANIB VERSUS SUNITINIB ON RENAL OUTCOME IN METASTATIC RENAL CELL CARCINOMA
    Lee, Eun Jeong
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 : 561 - 561
  • [37] A real-world experience of immune checkpoint inhibitors (ICI) in metastatic renal cell carcinoma (mRCC)
    Elias, Roy
    Levonyak, Nicholas
    Christie, Alana
    Bowman, Isaac Alexander
    Kapur, Payal
    Hannan, Raquibul
    Hammers, Hans J.
    Brugarolas, James
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [38] Nivolumab in metastatic renal cell carcinoma (mRCC) patients: a real world single-center experience
    Ratta, R.
    Grassi, P.
    Verzoni, E.
    Mennitto, A.
    de Braud, F.
    Procopio, G.
    ANNALS OF ONCOLOGY, 2016, 27
  • [39] COST-UTILITY ANALYSIS OF PAZOPANIB VERSUS SUNITINIB AS FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC) IN SPAIN
    Espinosa, J.
    Gonzalez-Larriba, J. L.
    Maroto, P.
    Mendez-Vidal, M. J.
    Diaz-Cerezo, S.
    VALUE IN HEALTH, 2014, 17 (07) : A632 - A633
  • [40] Australian Treatment Practices for Patients with Metastatic Renal Cell Carcinoma (MRCC)
    Liow, Elizabeth
    Baenziger, Olivia
    Corrente, Claudia
    Law, Nicholas
    Azad, Arun
    Shapiro, Julia
    Shapiro, Jeremy
    Weickhardt, Andrew
    Schmidt, Andrew
    Parnis, Francis
    Wong, Shirley
    Parente, Phillip
    Anton, Angelyn
    Pezaro, Carmel
    Tran, Ben
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 55 - 55
12345